Celldex Therapeutics, Inc. $CLDX Shares Sold by Eventide Asset Management LLC

Eventide Asset Management LLC lessened its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 11.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,642,559 shares of the biopharmaceutical company’s stock after selling 216,536 shares during the period. Eventide Asset Management LLC’s holdings in Celldex Therapeutics were worth $44,607,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in the company. Segall Bryant & Hamill LLC increased its position in Celldex Therapeutics by 36.3% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 528,597 shares of the biopharmaceutical company’s stock valued at $13,675,000 after acquiring an additional 140,709 shares during the period. Propel Bio Management LLC purchased a new stake in shares of Celldex Therapeutics during the 3rd quarter worth approximately $4,010,000. American Century Companies Inc. lifted its stake in Celldex Therapeutics by 4.6% in the 3rd quarter. American Century Companies Inc. now owns 815,560 shares of the biopharmaceutical company’s stock valued at $21,099,000 after buying an additional 35,575 shares in the last quarter. Braidwell LP purchased a new stake in Celldex Therapeutics in the 3rd quarter valued at approximately $15,307,000. Finally, Envestnet Asset Management Inc. raised its holdings in Celldex Therapeutics by 50.4% in the 3rd quarter. Envestnet Asset Management Inc. now owns 63,594 shares of the biopharmaceutical company’s stock valued at $1,645,000 after acquiring an additional 21,307 shares during the last quarter.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CLDX. UBS Group increased their price target on Celldex Therapeutics from $38.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday. Wolfe Research raised shares of Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price target on the stock in a research report on Monday, March 23rd. Wall Street Zen raised shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Barclays increased their price target on shares of Celldex Therapeutics from $45.00 to $48.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Finally, Wells Fargo & Company increased their price target on shares of Celldex Therapeutics from $38.00 to $54.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $49.30.

Celldex Therapeutics Stock Up 4.4%

Shares of NASDAQ CLDX opened at $31.27 on Friday. The firm’s 50-day moving average price is $31.88 and its two-hundred day moving average price is $28.83. Celldex Therapeutics, Inc. has a 52-week low of $19.52 and a 52-week high of $35.79. The stock has a market capitalization of $2.45 billion, a P/E ratio of -7.34 and a beta of 0.95.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.80 million. As a group, equities research analysts expect that Celldex Therapeutics, Inc. will post -4.36 earnings per share for the current year.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.